Last reviewed · How we verify
NCT00002552
AUTOLOGOUS, ALLOGENEIC, OR SYNGENEIC BONE MARROW TRANSPLANTATION IN HODGKIN'S DISEASE, NON-HODGKIN'S LYMPHOMA, AND MULTIPLE MYELOMA
Phase 2 trial testing filgrastim in Lymphoma in 40 participants. Completed in 1 October 2003.
1 September 2001
Quick facts
| Lead sponsor | Barbara Ann Karmanos Cancer Institute |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 1 October 1993 |
| Primary completion | 1 September 2001 |
| Estimated completion | 1 October 2003 |
| Sites | 1 location across United States |
Drugs / interventions tested
- filgrastim
- sargramostim (SARGRAMOSTIM) — full drug profile →
- carmustine (CARMUSTINE) — full drug profile →
- cyclophosphamide (cyclophosphamide) — full drug profile →
- cytarabine — full drug profile →
- etoposide
- leucovorin calcium
- methotrexate
- perfosfamide (PERFOSFAMIDE) — full drug profile →
- therapeutic hydrocortisone
- allogeneic bone marrow transplantation
- autologous bone marrow transplantation
- in vitro-treated bone marrow transplantation
- peripheral blood stem cell transplantation
- syngeneic bone marrow transplantation
- radiation therapy
Conditions studied
- Lymphoma — all drugs for Lymphoma →
- Multiple Myeloma and Plasma Cell Neoplasm — all drugs for Multiple Myeloma and Plasma Cell Neoplasm →
Sponsor
Barbara Ann Karmanos Cancer Institute
Who can join
Under 70, any sex, with Lymphoma or Multiple Myeloma and Plasma Cell Neoplasm. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining bone marrow transplantation with chemotherapy may allow doctors to give higher doses of chemotherapy and kill more tumor cells. PURPOSE: This phase II trial is studying the side effects of giving a bone marrow transplant together with chemotherapy and to see how well it works in treating patients with refractory non-Hodgkin's lymphoma, Hodgkin's lymphoma, or multiple myeloma.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT00002552
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of filgrastim
Trials testing the same drug.
- NCT06926751 — Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid Tumors · Phase 2 · not yet recruiting
- NCT04023669 — Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Re · Phase 1 · completed
- NCT03434262 — SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children · Phase 1 · completed
- NCT02029638 — BMT and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance · Phase 2 · terminated
- NCT01707004 — Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients · Phase 2 · completed
Other recruiting trials for Lymphoma
Currently open trials in the same condition.
- NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
- NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
- NCT06856226 — Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing · recruiting
- NCT07226934 — An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers · NA · recruiting
- NCT07138547 — GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma · Phase 1, PHASE2 · recruiting
Other Barbara Ann Karmanos Cancer Institute trials
Trials by the same sponsor.
- NCT07343297 — Ask Questions About Clinical Trials · NA · not yet recruiting
- NCT07118202 — TheraBionic P1 Device in Subjects With Advanced Hepatocellular Carcinoma · NA · recruiting
- NCT07098299 — Metformin Combined With Chemotherapy and/or Immunotherapy in Solid Malignancies · Phase 1 · recruiting
- NCT07130903 — Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Met · Phase 2 · recruiting
- NCT07095114 — A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients. · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00002552 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Barbara Ann Karmanos Cancer Institute
- Last refreshed: 5 April 2013
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00002552.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing